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Summary
Numerous case series have addressed the concern that
cancer therapy may damage germ cells, leading to clin-
ical disease in offspring of survivors. None has docu-
mented an increased risk. However, the methodological
problems of small series make it difficult to draw firm
conclusions regarding the potential of cancer treatments
to damage the health of future offspring. We conducted
a large interview study of adult survivors of childhood
cancer treated before 1976. Genetic disease occurred in
3.4% of 2,198 offspring of survivors, compared with
3.1% of 4,544 offspring of controls ( ; not sig-P  .33
nificant); there were no statistically significant differ-
ences in the proportion of offspring with cytogenetic
syndromes, single-gene defects, or simple malforma-
tions. A comparison of survivors treated with potentially
mutagenic therapy with survivors not so treated showed
no association with sporadic genetic disease ( ).P  .49
The present study provides reassurance that cancer treat-
ment using older protocols does not carry a large risk
for genetic disease in offspring conceived many years
after treatment. With 80% power to detect an increase
as small as 40% in the rate of genetic disease in offspring,
this study did not do so. However, we cannot rule out
the possibility that new therapeutic agents or specific
combinations of agents at high doses may damage germ
cells.
Received June 27, 1997; accepted for publication November 5,
1997; electronically published January 16, 1998.
Address for correspondence and reprints: Dr. Julianne Byrne, De-
partment of Hematology/Oncology, Children’s National Medical Cen-
ter, 111 Michigan Avenue NW, Washington, DC 20010. E-mail:
jbyrne@cnmc.org
*Formerly staff members of the National Cancer Institute.
†Formerly with the California Tumor Registry.
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6201-0010$02.00
Introduction
Survival in children and adolescents with cancer has in-
creased significantly in recent decades, owing to ad-
vances in therapy. Although childhood cancer is still a
life-threatening disease (Ries et al. 1994), overall survival
of 170% has increased concerns for long-term adverse
consequences of therapy, including effects on intellectual
functioning and on fertility, as well as on genetic disease
in offspring.
Concerns for the effects that cancer treatment may
have on the health of an unconceived child are well
founded. The high doses of radiation and chemothera-
peutic agents used to treat childhood cancer cause al-
terations in DNA and are mutagenic in animal models
and in in-vitro assays (Epstein 1990; Russell et al. 1981;
Hales et al. 1992; DeMarini et al. 1989). Previous studies
typically enrolled small numbers of survivors of many
types of childhood cancer, and surveillance bias and re-
porting bias were not adequately controlled. Although
these studies showed little or no increase in the risk of
genetic disease in offspring, their methodological prob-
lems, including small sample size, make it difficult to
draw reassuring conclusions (earlier studies have been
summarized in Mulvihill and Byrne 1985; Mulvihill et
al. 1987a; Hawkins 1991; Aisner et al. 1993; Dodds et
al. 1993; Kenney et al. 1996; Green et al. 1989, 1997).
The issue of genetic disease in offspring of cancer sur-
vivors is important not only for counseling of cancer
survivors but also for the larger question of induction
of human germ-cell mutation by environmental agents
such as radiation or toxic emissions. Elsewhere we ex-
amined the risk of cancer in the offspring of cancer sur-
vivors and found no significantly increased risk attrib-
utable to cancer therapy (Mulvihill et al. 1987a). In the
present report we evaluate the hypothesis that cancer
therapy causes no clinically detectable increased risk of
genetic disease (defined as a birth defect, a cytogenetic
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abnormality, a single-gene defect, or altered sex ratio)
in cancer survivors’ offspring conceived after their par-
ents’ treatment had ceased. Information on the presence
of genetic disease in the offspring of cancer survivors
and in the offspring of controls was obtained by inter-
view; medical-record documentation was obtained
where possible. To refine the exposures and outcomes,
we restricted the final analyses to survivors with poten-
tially mutagenic exposures and to offspring with spo-
radic genetic disease.
Although this is the first large study of childhood can-
cer survivors that evaluates the issue of germ-cell mu-
tagenesis, and although our results are generally reas-
suring, nevertheless the older therapies received by this
cohort may not predict the effects of newer protocols.
However, the totality of late effects experienced by even
older cancer survivors is still not known. Early mortality,
even decades after treatment, is among the problems
coming to light only now (Nicholson et al. 1994). More-
recent cohorts, in their turn, must wait decades for their
experiences to be described.
Subjects and Methods
Subjects
The National Cancer Institute collaborated with three
hospital-based cancer registries (University of Iowa, Uni-
versity of Kansas, and University of Texas–M. D. An-
derson Hospital) and two population-based registries
(California Department of Health Services and Yale Uni-
versity for the Connecticut Tumor Registry) in the Five
Center Study. Eligible cancer survivors must have met
the following requirements: (1) histologically diagnosed
malignant neoplasm or any CNS neoplasm in a person
!20 years of age at diagnosis (basal- and squamous-cell
skin cancers excluded), (2) diagnosis during 1945–75,
(3) survival for x5 years after diagnosis, and (4) at-
tainment of 21 years of age by December 31, 1979. At
the time of interview, survivors were asked for permis-
sion to review hospital and physician records and to
contact siblings. When possible, as many as two controls
were selected from among survivors’ siblings. To be in-
cluded, siblings had to have reached 19 years of age by
December 31, 1979, and they were matched as closely
as possible with regard to full sibship, sex, and date of
birth, in that order.
Interviews were completed with 91% of eligible sur-
vivors and 91% of eligible controls. Reasons for not
interviewing included failure to locate the subject or re-
fusal by the subject, physician, or subject’s next of kin.
Proxy interviews were obtained for 10% of survivors
and 4% of controls. No statistically significant differ-
ences were observed between survivors and controls,
with respect to center, sex, or race. Interviews were con-
ducted between August 1980 and April 1983 by trained
interviewers. Both survivors and controls were asked
about demographic characteristics, family history, and
medical history. Details about tumors and therapy were
abstracted from tumor-registry and hospital records. We
defined “potentially mutagenic therapy” as either radi-
otherapy given below the diaphragm and above the
knees or chemotherapy with an alkylating agent. Al-
kylating agents used were chlorambucil, cyclophos-
phamide, mechlorethamine, procarbazine, triethylene-
thiophosphoramide, busulfan, and melphalan. All other
therapies were defined as “nonmutagenic.”
Offspring
To be eligible for this analysis, a child of a survivor
had to be born not less than 9 mo after the parent’s
cancer diagnosis, ensuring that the survivor had been
exposed to some therapy before the child was conceived.
Offspring of controls had to be born after their parent
had reached the same age as the cutoff for the matched
survivor sibling. These requirements yielded 2,198 off-
spring of survivors and 4,544 offspring of controls (table
1). At follow-up, the mean age of offspring of survivors
and the mean age of offspring of controls were 10.6
years ( years) and 11.4 years ( years),SD  7.2 SD  8.0
respectively.
At interview, subjects were asked specifically about
each conception and live-born child. One question in-
quired about “conditions sometimes present at or soon
after birth” and referred the subject to two printed lists
of conditions. The list entitled “Health Conditions at
Birth” included the following: crossed eyes (strabismus);
stomach blockage (pyloric stenosis); hole in roof of
mouth (cleft palate); hare lip (cleft lip); rupture in groin
(inguinal hernia); clubfoot; absent, fused, or extra fingers
or toes; hole in the heart; hip displacement; diverted
urinary stream (hypospadias); mongolism (Down syn-
drome); open spine (spina bifida); water on the brain
(hydrocephalus); exposed brain (anencephaly); undes-
cended testicle (cryptorchidism); prematurity; hyaline-
membrane disease; and other conditions. The second list,
entitled “Other Conditions,” included achondroplasia,
acrocephalosyndactyly, aniridia, Apert syndrome, can-
cer, dystrophia myotonica, Gardner syndrome, Marfan
syndrome, multiple polyposis, neurofibromatosis, osteo-
genesis imperfecta, polycystic disease of the kidney,
Recklinghausen disease, retinoblastoma, and Steinert
syndrome. Efforts to verify the reported condition
through review of hospital records, death certificates,
and cancer-treatment records were made for each re-
ported event. All disorders were included in the analysis
unless records specifically denied the report.
“Genetic disease” was defined as a syndrome of mal-
formations known to have an associated cytogenetic ab-
Byrne et al.: Genetic Disease in Offspring 47
Table 1
Numbers of Cancer Survivors, Sibling Controls, and Offspring, by
Sex
Group
No. of
Survivors
No. of
Controls
Subjects:
Males 436 912
Females 626 1,120
Subtotal 1,062 2,032
Offspring:
Of male subjects:
Male offspring 468 1,022
Female offspring 448 1,021
Subtotal 916 2,043
Of female subjects:
Male offspring 644 1,278
Female offspring 638 1,223
Subtotal 1,282 2,501
Total 2,198 4,544
normality (regardless of whether karyotypes were avail-
able), a single-gene (i.e., Mendelian) disorder, or any one
of 15 common simple birth defects. A condition was
described as “sporadic” if, in the opinion of two re-
viewing physicians, no relative had the same or related
genetic disease. All recessive disorders were called “fa-
milial” (nonsporadic), since both parents were gene car-
riers. If a child had both a familial condition and a spo-
radic condition, then the child was classified as sporadic;
when the number of genetic conditions was tabulated,
only the condition determined to be sporadic was
counted. x2 Analysis and Fisher’s exact test were used
to test statistical significance.
Results
Among the 1,062 eligible survivors, the most fre-
quently observed type of neoplasm was Hodgkin disease,
which accounted for 18% of survivors. Next in fre-
quency were soft-tissue sarcomas (14%), thyroid-gland
cancers (14%), and brain and other CNS neoplasms
(12%). All other cancers accounted for the remainder.
Mean age at diagnosis of cancer was 13.5 years and
14.0 years, for male and female survivors, respectively.
Table 2 classifies the treatment received by survivors,
into potentially mutagenic and nonmutagenic therapies.
The majority (72.8%) of survivors received nonmuta-
genic therapy, whereas 22.1% received therapy that
could be classified as potentially mutagenic. The likeli-
hood of being treated with potentially mutagenic ther-
apy increased with time: 16% of survivors in this study
who were diagnosed with cancer during 1945–54 re-
ceived potentially mutagenic therapy, compared with
32% for the years 1965–74.
The rate of genetic disease in the offspring of survivors
was 3.4%, compared with 3.1% in the offspring of con-
trols (table 3); this difference was not statistically sig-
nificant. The rate of genetic disease was also examined
separately for male and female subjects; again, no sig-
nificant difference between survivors and controls was
observed. However, female survivors were more likely
than male survivors to report children with a birth defect
(4.0% vs. 2.5%, ; [two-tailed test]).2x  3.1 P  .08
There was no difference between female controls and
male controls.
When types of genetic disease (cytogenetic syndromes,
single-gene defects, and simple malformations) were ex-
amined individually, the differences, in rates of these
defects, between offspring of survivors and offspring of
controls were not statistically significant (table 4), either
overall or for each type. Down syndrome occurred at
approximately the same rate in both groups—1.3/1,000
in survivors’ offspring and 0.88/1,000 in controls’ off-
spring. Neither rate was different from the expected rate
of 0.8/1,000 (James 1993; table 5). Individual single-
gene defects did not occur more frequently among sur-
vivors’ offspring (data not shown). To see whether over-
all rates concealed differences in specific types of mal-
formations, we compared rates of occurrence of 15 types
of simple malformations in the two groups; no single
type of malformation occurred to excess among off-
spring of survivors compared with offspring of controls
(table 6). However, although the rates of heart defects
were not different between survivors’ offspring and con-
trols’ offspring, both rates were higher than expected
(55/10,000 and 46/10,000, respectively, for septal de-
fects), compared with the reported 1-year prevalence of
all heart defects, which is 37/10,000 (Ferencz et al.
1985). But many heart defects are not diagnosed until
later in childhood (Correa-Villasenor et al. 1991). Since
offspring in the present study were 11 years of age at
the time of the interview, it is likely that length of as-
certainment explains the relatively high rate of heart
defects.
Finally, we constructed a nested case-control study
within this cohort study, to determine the odds of spo-
radic genetic disease in offspring of survivors only, com-
paring those who had received potentially mutagenic
therapy versus those who had received nonmutagenic
therapy. The odds ratio was virtually at unity (OR 
; 95% confidence interval 0.48–2.01), indicating no.99
association (table 7).
Survivor pregnancies and control pregnancies were
analyzed with regard to possible confounding factors,
including both parental age at birth of the offspring and
exposures, during each pregnancy, to cigarettes, alcohol,
rubella, herpes, and x-rays. These factors did not differ
significantly between survivors and controls, with the
exception of x-ray exposure during pregnancy; 20.8%
of survivors’ pregnancies were exposed to radiation,
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Table 2
Anticancer Therapy Received by Survivors
Type of Therapy No. (%)
Potentially mutagenic:
Radiotherapy below diaphragm only 87 (8.2)
Radiotherapy below diaphragm/
chemotherapy with alkylating agent 49 (4.6)
Chemotherapy with alkylating agent
only 46 (4.3)
Radiotherapy above diaphragm/
chemotherapy with alkylating agent 34 (3.2)
Radiotherapy below diaphragm/
chemotherapy (no alkylating agent) 14 (1.3)
Radiotherapy of unknown site/
chemotherapy with alkylating agent 5 (.5)
Subtotal 235 (22.1)
Nonmutagenic:
No radiotherapy or chemotherapy 550 (51.8)
Radiotherapy above diaphragm only 193 (18.2)
Chemotherapy only (no alkylating
agent) 18 (1.7)
Radiotherapy above diaphragm/
chemotherapy (no alkylating agent) 12 (1.1)
Subtotal 773 (72.8)
Unclassifiable:
Radiotherapy only of unknown site 51 (4.8)
Radiotherapy of unknown site/
chemotherapy (no alkylating agent) 3 (.3)
Subtotal 54 (5.1)
Total 1,062 (100)
Table 3
Genetic Disease in Offspring of Cancer Survivors and in Offspring
of Sibling Controls, by Sex of Subject’s Parent
NO. OF OFFSPRING WITH GENETIC DISEASE/TOTAL
NO. OF OFFSPRING, OFa
Survivors Controls
Femalesb 51/1,282 (4.0%) 75/2,501 (3.0%)
Malesb 23/916 (2.5%) 67/2,043 (3.3%)
Total 74/2,198 (3.4%) 142/4,544 (3.1%)
a Comparison of survivors to controls yields and2x  0.3 P  .3
(one-tailed test).
b Comparison of female to male survivors yields and2x  3.1
(two-tailed test).P  .08
compared with 17.2% of controls’ pregnancies ( 2x 
; ).12.8 P  .0003
To follow up on the unexpected finding in table
3—that is, that female survivors had more children with
birth defects than did male survivors—we evaluated the
percentage of offspring with genetic disease, both ac-
cording to their parents’ cancer and according to
whether the genetic disease was sporadic or familial.
None of these strata demonstrated a statistically signif-
icant difference ( ) between male survivors andP ! .05
female survivors, suggesting that this is a possibly spu-
rious finding.
Alterations in the sex ratio of offspring of survivors
may indicate genetic damage. We evaluated the sex ratio
of offspring born to male survivors and to female sur-
vivors, compared with that of offspring born to controls
(1.05 vs. 1.00, respectively, for males, and 1.01 vs. 1.05,
respectively, for females; table 1). Neither difference
reached statistical significance. Next, we restricted the
comparisons to survivors only, comparing survivors
treated with potentially mutagenic therapy versus those
without this treatment. The sex ratio of offspring of male
survivors receiving potentially mutagenic therapy was
1.06, versus 1.01 for offspring of male survivors treated
with other therapies ( ; ). For offspring2x  0.10 P  .8
of female survivors, the respective sex ratios were 0.84
and 1.03, again not statistically significantly different
( ; ).2x  1.7 P  .2
Discussion
Our study demonstrates no statistically significant dif-
ference in the risk of genetic disease among offspring of
childhood-cancer survivors, compared with that in off-
spring of sibling controls. As the largest study to date
with results consistent with findings from earlier reports,
the present study provides reassurance that cancer ther-
apy in use during 1945–75 did not carry a large risk for
clinically detectable genetic disease in offspring con-
ceived many years after their parents’ therapy was fin-
ished. Although the relatively old age of participants
means that relatively out-of-date therapies were being
evaluated, it must be borne in mind that this situation
will always apply. Studies of fertility and offspring in
people exposed as children must always wait decades to
be done. The mutagenic potential of today’s therapies
cannot be evaluated for perhaps decades, as we wait for
these patients to become adults. Very large studies of
patients treated for cancer with new drugs are needed
to evaluate the potential for mutagenicity of new ther-
apies. Two new studies of patient cohorts treated during
the 1980s and early 1990s are currently being
implemented.
The strength of this study lies in its statistical power
and ability to control potential biases. The study’s power
to detect a doubling in the risk of genetic disease in
offspring is 190% ( [two-tailed test]); a nesteda  .05
case-control study with a power of 80% failed to find
an increase in germ-cell damage unless such increase was
140% (table 7). Inclusion of controls meant reduced
potential for surveillance bias. Increased medical so-
phistication of survivors would mean greater awareness
of their children’s health, leading to surveillance bias;
inclusion of sibling controls who would share some of
their siblings’ health concerns would tend to equalize
this bias. Offspring of both groups were similar in age,
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Table 4
Genetic Disease in Offspring of Cancer Survivors and in Offspring of
Sibling Controls
TYPE OF GENETIC
DISEASE
NO. (%) OF OFFSPRING WITH GENETIC
DISEASE, OF
Survivors (n  2, 198) Controls ( )n  4, 544
Cytogenetic syndrome 4 (0.2) 6 (0.1)
Single-gene disorder 14 (0.6) 10 (0.2)
Simple malformation 59 (2.7) 127 (2.8)
Totala 74 (3.4) 142 (3.1)
a The totals are less than the sums of the categories because offspring
may have more than one type of genetic disease.
Table 5
Cytogenetic Syndromes in Offspring of Cancer Survivors and in
Offspring of Sibling Controls
CYTOGENETIC
SYNDROME
NO. OF OFFSPRING OF
Survivors Controls
Down 3 4
Turner 1 1a
Cri-du-chat 0 1
Total 4 6
a Parent stated that there were a “chromosome defect and no ovaries
at birth.”
making the potential for late ascertainment of birth de-
fects comparable.
We found, as did Hawkins (1991), no significant dif-
ferences in the sex ratio of offspring, whether overall,
by the sex of the survivor parent, or between subgroups
of survivors who did or who did not receive potentially
mutagenic therapy. The theory is that exposed mothers
could give birth to fewer male offspring because of an
increase in X-linked lethal mutations, whereas exposed
fathers could show an increased sex ratio because of X-
linked dominant mutations (Scholte and Sobel 1964). In
this study the sex ratio of offspring of females exposed
to mutagenic therapy was decreased (0.84; not signifi-
cant), compared with that in offspring of unexposed
survivors, which would be expected if an effect were
present.
There were no differences in rates of cytogenetic dis-
eases, single-gene defects, or simple malformations in
offspring when survivors were compared with sibling
controls. However, compared with rates derived from
registries and special studies, both groups in this study
had higher rates of heart defects, possibly because of
surveillance bias and/or a longer period of observation
(Ferencz et al. 1985; James 1993). Many heart defects
are diagnosed late in the 1st year of life and even into
the 2d year of life (Ferencz et al. 1985). We and others
have evaluated the suggestion that treatment with dac-
tinomycin might be associated with heart defects, and,
in the present study, we found no children with heart
defects who were born to mothers exposed to dactino-
mycin (Green et al. 1991; Byrne et al. 1992). Investi-
gators who evaluate the potential of cancer treatment
to produce heart defects in offspring ascertained
throughout childhood may find a spuriously raised rate
if controls are not comparable.
Individuals with cancer-susceptibility syndromes
whose cancer treatment includes mutagenic agents may
produce excess offspring with either cancer or birth de-
fects. Although theoretically this is possible, the excess
would be small and, except in a special study, hard to
detect. We did not see any suggestion of such an excess
when we evaluated genetic disease on the basis of type
of tumor.
The presence of germ-line mutations may be indicated
by other outcomes, such as either cancer in the offspring
or early spontaneous abortions. At least three studies
have evaluated a potential raised risk of cancer in the
offspring of survivors; none found a significantly greater
risk than expected, after exclusion of known familial
cancers (Mulvihill et al. 1987b; Dodds et al. 1993; Haw-
kins et al. 1995).
Recognized miscarriages have not been convincingly
linked to cancer treatment considered as a mutagenic
exposure. However, excess miscarriages occur among
the pregnancies of women treated with radiotherapy be-
low the diaphragm, possibly as a result of direct radi-
ation of the uterus (Li et al. 1987; Byrne et al. 1988;
Hawkins and Smith 1989;Hawkins 1994). Uterine
anomalies also occur to excess in girls with Wilms tumor
and may result in miscarriages independently of therapy
(Nicholson et al. 1996).
Early unrecognized miscarriages may be observed as
infertility, which is a common result both of treatment
with high-dose abdominal radiotherapy and of alkylat-
ing agents. A previous report from this study showed
that radiation therapy below the diaphragm depressed
fertility in both sexes and that chemotherapy with al-
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Table 6
Simple Malformations in Offspring of Cancer Survivors and in
Offspring of Sibling Controls, and Rate/10,000 Live Births
MALFORMATION
NO. OF OFFSPRING WITH MAL-
FORMATIONS (RATE/10,000
LIVE BIRTHS), OF
PaSurvivors Controls
Anencephaly 0 (0) 2 (1) NS
Spina bifida 9 (2) 9 (4) NS
Hydrocephalus 9 (2) 0 (0) NS
Transposition of the
great vessels
0 (0) 4 (2) NS
Septal defects 55 (12) 46 (21) NS
Patent ductus 23 (5) 13 (6) NS
Cleft lip without cleft
palate
14 (3) 7 (3) NS
Cleft lip with or
without cleft
palate
9 (2) 9 (4) NS
Tracheo-esophageal
fistula
5 (1) 0 (0) NS
Rectal atresia/stenosis 5 (1) 2 (1) NS
Hypospadias 23 (5) 18 (8) NS
Clubfoot 73 (16) 106 (48) NS
Limb-reduction
deformity
5 (1) 20 (9) NS
Hip dislocation 55 (12) 66 (30) NS
Renal agenesis 0 (0) 4 (2) NS
a NS  not significant.
Table 7
Risk of Sporadic Genetic Disease in Offspring of Cancer Survivors,
by Type of Treatment Received
SPORADIC
GENETIC
DISEASE STATUS
NO. (%) ADMINISTERED THERAPY TYPE
Potentially Mutagenic Nonmutagenic
Positive 11 (2.7) 46 (2.7)
Negative 397 (97.3) 1,647 (97.3)
NOTE.— ; (one-tailed test).2x  0.0004 P  .49
kylating agents was associated with decreased fertility
in male survivors (Byrne et al. 1987). Although it may
represent genetic damage, infertility is a complicated out-
come, with many causes. A genetic etiology for infertility
has not been studied.
Another possible reason for the lack of clinically ob-
servable genetic damage in our study may be that the
mutant phenotype is below the threshold of detection
for clinical events (Crow and Denniston 1984). More
detailed biological studies of abnormalities in electro-
phoretic mobilities of proteins or alterations in DNA in
future cohorts of cancer survivors may reveal more sub-
tle damage (Mohrenweiser et al. 1989).
Despite the large sample size of our study, fewer than
one quarter of the survivors were exposed to potentially
mutagenic therapy. Furthermore, this study is limited in
its power to detect small changes in either (a) the risk
of new (spontaneous) mutations or (b) risks due to in-
dividual agents or specific combinations of agents. One
study of 69,277 infants found, in the first 5 d of life,
only 11 detectable malformations that could be attrib-
uted to new (spontaneous) mutations (Nelson and
Holmes 1989). A much larger sample size than our study
would be necessary to detect a doubling of this very low
rate, and that would require international collaboration.
Quantification of the dosages of radiation and che-
motherapeutic agents was not attempted in our survivors
because of the complex nature of this estimation. As a
result, we are unable to consider dose-response rela-
tionships. Similarly, we have not considered separately
patients who received combinations of chemotherapeu-
tic agents. Cancer treatments are continually being mod-
ified in the search for more effective, less toxic therapies.
Although radiation doses have fallen, newer chemo-
therapeutic agents and higher doses of potentially mu-
tagenic drugs are commonplace.
As new chemotherapeutic agents are introduced, con-
cern over their potential for germ-cell damage will con-
tinue. Some drugs, such as diethylstilbestrol, are carcin-
ogenic and teratogenic if administered during pregnancy
(Mittendorf 1995). Although animal studies have limited
ability to provide reassurance for human therapies, such
studies nevertheless have provided much of the basis for
the concern about germ-cell mutagenesis. For instance,
cyclophosphamide in high doses causes heritable damage
in F2 generations after exposure of male rats (Hales et
al. 1992). After irradiation and treatment with urethane,
a potent mutagen, male and female mice produced more
offspring with tumors and congenital anomalies (No-
mura 1982).
Several other types of studies have addressed the ques-
tion of germ-cell mutation in humans exposed to radi-
ation before conception. Extrapolation from animal
models may be limited if, as is suggested, humans are
less sensitive to the mutagenic effects of radiation (Neel
et al. 1990). Other studies have associated radiation ex-
posure of parents with a raised risk, in offspring, of
leukemia, lymphoma, and Down syndrome (Gardner et
al. 1990; Shu et al. 1994; Bound et al. 1995). The major
study addressing this issue is the follow-up of offspring
of atomic-bomb survivors in Hiroshima and Nagasaki.
The indicators of genetic damage that were used were
sex ratio, birth weight, anthropometric data, and fre-
quencies of stillbirths, neonatal deaths, and gross mal-
formations. Further studies include cytogenetic evalua-
tion of individuals who had reached 13 years of age,
examination of survival of offspring, and alteration of
the electrophoretic patterns of proteins. None of these
measures has shown any statistically significant associ-
ation with parental exposure (Neel and Schull 1991).
However, the authors point out that their findings are
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in the direction expected if the hypothesis of genetic
damage is correct. More recently, reports of germ-cell
mutagenesis in animals after the Chernobyl disaster pro-
vide evidence for inherited mutations in this context (El-
lergren et al. 1997).
Some difficulties inherent in the method used to collect
information in this study must be recognized. The as-
certainment of birth defects in survivor offspring and in
control offspring relied on interviews with parents, with
documentation sought for positive reports, a method
that may underestimate the true rate (Rasmussen et al.
1990). However, if a difference exists, then one would
expect to overestimate birth defects in offspring of sur-
vivors, because of their heightened knowledge of medical
conditions, a bias in the direction of our hypothesis, a
result that, again, tends to strengthen our negative find-
ings. The use of interview data has an advantage, how-
ever, over either examination of newborns or review of
medical records, in that conditions that may manifest
themselves later in life are more likely to be ascertained.
We were careful to exclude the possibility of teratogenic
exposures, which might have led to a spurious
association.
In conclusion, our study demonstrates no increased
risk of genetic disease, as defined herein, in offspring of
cancer survivors treated before 1976, compared with the
risk in offspring of sibling controls. This information is
important for clinical counseling of individuals who
have survived childhood or adolescent cancer; patients
can be reassured that their risk of a child with a birth
defect is not likely to be greater than that in the general
population. However, this study cannot rule out a small
increase in risk(s) associated with exposure to specific
agents delivered at high doses. Furthermore, the issue of
biological changes associated with cancer treatment that
do not result in functional or anatomic problems has
not been addressed here and therefore remains an open
question. The numbers of patients needed to satisfac-
torily answer questions about the potential mutagenicity
of either single-agent therapies or specific combinations
of therapies are considerable, and this problem must be
addressed in a multi-institutional and/or international
setting. The causes of most birth defects and childhood
cancer are not at all understood. In a time of increasing
rates of many cancers, including those of childhood
(Gurney et al. 1996), comprehensive studies such as
these become increasingly important and must be
undertaken.
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